Exicure (NASDAQ:XCUR) Announces Earnings Results

Exicure (NASDAQ:XCUR) posted its quarterly earnings data on Wednesday. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.14, FiscalAI reports.

Exicure Stock Performance

Shares of XCUR stock opened at $4.61 on Friday. Exicure has a fifty-two week low of $3.10 and a fifty-two week high of $14.73. The company has a 50 day moving average price of $4.38 and a 200 day moving average price of $4.66. The stock has a market capitalization of $29.37 million, a P/E ratio of -5.99 and a beta of 4.13.

Analysts Set New Price Targets

A number of brokerages recently commented on XCUR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. Wall Street Zen upgraded Exicure to a “hold” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure currently has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.